{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:43:28Z","timestamp":1771332208517,"version":"3.50.1"},"reference-count":82,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fondo de Investigaciones Sanitarias (FIS) of the Instituto de Salud Carlos III","award":["PI16\/00642, FEDER"],"award-info":[{"award-number":["PI16\/00642, FEDER"]}]},{"name":"the Consejer\u00eda de Educaci\u00f3n (Regional Government of Castilla and Le\u00f3n, Spain)","award":["SA013U16"],"award-info":[{"award-number":["SA013U16"]}]},{"name":"Biomedical Research Networking Centre on Cancer","award":["CIBERONC CB16\/12\/00400"],"award-info":[{"award-number":["CIBERONC CB16\/12\/00400"]}]},{"name":"Asociaci\u00f3n Espa\u00f1ola de Mastocitosis y Enfermedades Relacionadas","award":["AEDM 2017"],"award-info":[{"award-number":["AEDM 2017"]}]},{"name":"Fondos de Investigaci\u00f3n para Enfermedades Raras del Ministerio de Sanidad, Servicios Sociales e Igualdad,","award":["PT13\/0010\/0007"],"award-info":[{"award-number":["PT13\/0010\/0007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Despite recent therapeutic advances, systemic mastocytosis (SM) remains an incurable disease due to limited complete remission (CR) rates even after novel therapies. To date, no study has evaluated the expression on SM bone marrow mast cells (BMMC) of large panel of cell surface suitable for antibody-targeted therapy. In this study, we analyzed the expression profile of six cell-surface proteins for which antibody-based therapies are available, on BMMC from 166 SM patients vs. 40 controls. Overall, variable patterns of expression for the markers evaluated were observed among SM BMMC. Thus, CD22, CD30, and CD123, while expressed on BMMC from patients within every subtype of SM, showed highly variable patterns with a significant fraction of negative cases among advanced SM (aggressive SM (ASM), ASM with an associated clonal non-MC lineage disease (ASM-AHN) and MC leukemia (MCL)), 36%, 46%, and 39%, respectively. In turn, CD25 and Fc\u03b5RI were found to be expressed in most cases (89% and 92%) in virtually all BMMC (median: 92% and 95%) from both indolent and advanced SM, but with lower\/absent levels in a significant fraction of MC leukemia (MCL) and both in MCL and well-differentiated SM (WDSM) patients, respectively. In contrast, CD33 was the only marker expressed on all BMMC from every SM patient. Thus, CD33 emerges as the best potentially targetable cell-surface membrane marker in SM, particularly in advanced SM.<\/jats:p>","DOI":"10.3390\/ijms20030552","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T03:40:55Z","timestamp":1548733255000},"page":"552","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9633-1749","authenticated-orcid":false,"given":"Noelia","family":"Dasilva-Freire","sequence":"first","affiliation":[{"name":"Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Biomedical Research Networking Centre on Cancer\u2013CIBER-CIBERONC, Institute of Health Carlos III, 28029 Madrid, Spain"},{"name":"Spanish Network on Mastocytosis (REMA), 45071 Toledo and 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mayado","sequence":"additional","affiliation":[{"name":"Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Biomedical Research Networking Centre on Cancer\u2013CIBER-CIBERONC, Institute of Health Carlos III, 28029 Madrid, Spain"},{"name":"Spanish Network on Mastocytosis (REMA), 45071 Toledo and 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Teodosio","sequence":"additional","affiliation":[{"name":"Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333 Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Jara-Acevedo","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Biomedical Research Networking Centre on Cancer\u2013CIBER-CIBERONC, Institute of Health Carlos III, 28029 Madrid, Spain"},{"name":"Spanish Network on Mastocytosis (REMA), 45071 Toledo and 37007 Salamanca, Spain"},{"name":"Sequencing DNA Service (NUCLEUS), University of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n","family":"\u00c1lvarez-Twose","sequence":"additional","affiliation":[{"name":"Spanish Network on Mastocytosis (REMA), 45071 Toledo and 37007 Salamanca, Spain"},{"name":"Institute for the Study of Mastocytosis of Castilla La Mancha (CLMast), Virgen del Valle Hospital, 45071 Toledo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Matito","sequence":"additional","affiliation":[{"name":"Spanish Network on Mastocytosis (REMA), 45071 Toledo and 37007 Salamanca, Spain"},{"name":"Institute for the Study of Mastocytosis of Castilla La Mancha (CLMast), Virgen del Valle Hospital, 45071 Toledo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1757-7255","authenticated-orcid":false,"given":"Laura","family":"S\u00e1nchez-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Spanish Network on Mastocytosis (REMA), 45071 Toledo and 37007 Salamanca, Spain"},{"name":"Institute for the Study of Mastocytosis of Castilla La Mancha (CLMast), Virgen del Valle Hospital, 45071 Toledo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Caldas","sequence":"additional","affiliation":[{"name":"Spanish Network on Mastocytosis (REMA), 45071 Toledo and 37007 Salamanca, Spain"},{"name":"Sequencing DNA Service (NUCLEUS), University of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Henriques","sequence":"additional","affiliation":[{"name":"Spanish Network on Mastocytosis (REMA), 45071 Toledo and 37007 Salamanca, Spain"},{"name":"Institute for the Study of Mastocytosis of Castilla La Mancha (CLMast), Virgen del Valle Hospital, 45071 Toledo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8982-5663","authenticated-orcid":false,"given":"Javier I.","family":"Mu\u00f1oz-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Biomedical Research Networking Centre on Cancer\u2013CIBER-CIBERONC, Institute of Health Carlos III, 28029 Madrid, Spain"},{"name":"Spanish Network on Mastocytosis (REMA), 45071 Toledo and 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s C.","family":"Garc\u00eda-Montero","sequence":"additional","affiliation":[{"name":"Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Biomedical Research Networking Centre on Cancer\u2013CIBER-CIBERONC, Institute of Health Carlos III, 28029 Madrid, Spain"},{"name":"Spanish Network on Mastocytosis (REMA), 45071 Toledo and 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7906-9032","authenticated-orcid":false,"given":"J. Ignacio","family":"S\u00e1nchez-Gallego","sequence":"additional","affiliation":[{"name":"Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Biomedical Research Networking Centre on Cancer\u2013CIBER-CIBERONC, Institute of Health Carlos III, 28029 Madrid, Spain"},{"name":"Spanish Network on Mastocytosis (REMA), 45071 Toledo and 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Escribano","sequence":"additional","affiliation":[{"name":"Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Biomedical Research Networking Centre on Cancer\u2013CIBER-CIBERONC, Institute of Health Carlos III, 28029 Madrid, Spain"},{"name":"Spanish Network on Mastocytosis (REMA), 45071 Toledo and 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-7230","authenticated-orcid":false,"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[{"name":"Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Biomedical Research Networking Centre on Cancer\u2013CIBER-CIBERONC, Institute of Health Carlos III, 28029 Madrid, Spain"},{"name":"Spanish Network on Mastocytosis (REMA), 45071 Toledo and 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: A consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk. Res."},{"key":"ref_2","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., and Vardiman, J.W. (2008). Mastocytosis (mast cell disease). World Health Organization (WHO) Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues, IARC Press."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Teodosio","year":"2006","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"Morgado","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Lhermitte","year":"2013","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fmed.2017.00110","article-title":"Targeted Treatment Options in Mastocytosis","volume":"4","author":"Vaes","year":"2017","journal-title":"Front. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","article-title":"Mastocytosis: Current concepts in diagnosis and treatment","volume":"81","author":"Escribano","year":"2002","journal-title":"Ann. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/asheducation-2015.1.98","article-title":"Diagnosis and management of mastocytosis: An emerging challenge in applied hematology","volume":"2015","author":"Valent","year":"2015","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: A phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Matito","year":"2017","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: A randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","article-title":"Midostaurin: Its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis","volume":"2","author":"Stone","year":"2018","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"Gonzalez","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaci.2013.12.1090","article-title":"Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype","volume":"134","author":"Chan","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.leukres.2014.07.010","article-title":"Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412","volume":"38","author":"Visconte","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e4934","DOI":"10.1097\/MD.0000000000004934","article-title":"Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.14967","article-title":"How we diagnose and treat systemic mastocytosis in adults","volume":"180","author":"Scherber","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4155\/tde.13.88","article-title":"Cancer immunotherapy: Accomplishments to date and future promise","volume":"4","author":"Helmy","year":"2013","journal-title":"Ther. Deliv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2016.146563","article-title":"Advanced systemic mastocytosis: From molecular and genetic progress to clinical practice","volume":"101","author":"Ustun","year":"2016","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.beha.2010.07.003","article-title":"Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells","volume":"23","author":"Valent","year":"2010","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.iac.2014.01.012","article-title":"Treatment strategies in mastocytosis","volume":"34","author":"Siebenhaar","year":"2014","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.10.020","article-title":"Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes","volume":"125","author":"Teodosio","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/his.12221","article-title":"CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis","volume":"63","author":"Morgado","year":"2013","journal-title":"Histopathology"},{"key":"ref_26","first-page":"S207","article-title":"Successful Treatment of Systemic Mastocytosis Associated with AML-M2, t(8:21) in a Child Using MRC-based AML Chemotherapy along with Gemtuzumab","volume":"119","author":"Jeong","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/leu.2016.30","article-title":"Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia","volume":"30","author":"Gotlib","year":"2016","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3109\/10428190903470869","article-title":"Treatment of aggressive systemic mastocytosis with daclizumab","volume":"51","author":"Amin","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.leukres.2016.02.010","article-title":"Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin","volume":"44","author":"Borate","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: Results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","article-title":"Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia","volume":"30","author":"Kreitman","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199801153380304","article-title":"Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group","volume":"338","author":"Vincenti","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00007890-199901270-00016","article-title":"Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group","volume":"67","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","article-title":"Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group","volume":"350","author":"Nashan","year":"1997","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(12)62190-4","article-title":"Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): A randomised, double-blind, placebo-controlled trial","volume":"381","author":"Gold","year":"2013","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1474-4422(14)70039-0","article-title":"Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): A multicentre, randomised, double-blind extension trial","volume":"13","author":"Giovannoni","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00415-013-7196-4","article-title":"Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis","volume":"261","author":"Giovannoni","year":"2014","journal-title":"J. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Gold, R., Radue, E.W., Giovannoni, G., Selmaj, K., Havrdova, E., Stefoski, D., Sprenger, T., Montalban, X., Cohan, S., and Umans, K. (2016). Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol., 16.","DOI":"10.1186\/s12883-016-0635-y"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"ref_46","unstructured":"Horwitz, S., O\u2019Connor, O.A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N.L., Christensen, J.H., Morschhauser, F., and Domingo-Domenech, E. (2018). Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial. Lancet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.leu.2404434","article-title":"High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the alfa group","volume":"21","author":"Taksin","year":"2007","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"916","DOI":"10.18632\/oncotarget.1536","article-title":"Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial","volume":"5","author":"Renneville","year":"2014","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.healun.2008.03.006","article-title":"Heart transplantation in a patient with systemic mastocytosis","volume":"27","author":"Moro","year":"2008","journal-title":"J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1067\/mai.2003.49","article-title":"Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma","volume":"111","author":"Corren","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1067\/mai.2003.54","article-title":"Omalizumab improves asthma-related quality of life in patients with severe allergic asthma","volume":"111","author":"Finn","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1398-9995.2009.02259.x","article-title":"Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient","volume":"65","author":"Douglass","year":"2010","journal-title":"Allergy"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.anai.2010.04.011","article-title":"Omalizumab monotherapy for bee sting and unprovoked \u201canaphylaxis\u201d in a patient with systemic mastocytosis and undetectable specific IgE","volume":"104","author":"Filis","year":"2010","journal-title":"Ann. Allergyasthma Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2010.05.043","article-title":"Successful treatment of idiopathic anaphylaxis in an adolescent","volume":"126","author":"Pitt","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_58","first-page":"52","article-title":"Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy","volume":"45","author":"Paraskevopoulos","year":"2013","journal-title":"Eur. Ann. Allergy Clin. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2340\/00015555-1687","article-title":"Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis","volume":"94","author":"Kibsgaard","year":"2014","journal-title":"Acta Derm. Venereol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"903541","DOI":"10.1155\/2015\/903541","article-title":"Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab","volume":"2015","author":"Lieberoth","year":"2015","journal-title":"Case Rep. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations","volume":"73","author":"Vestergaard","year":"2018","journal-title":"Allergy"},{"key":"ref_62","first-page":"120","article-title":"Mast cell disorders: Protean manifestations and treatment responses","volume":"121","author":"Chen","year":"2018","journal-title":"Ann. Allergyasthma Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.0960-135X.2004.01369.x","article-title":"On the way to targeted therapy of mast cell neoplasms: Identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts","volume":"34","author":"Valent","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ajh.23931","article-title":"Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management","volume":"90","author":"Pardanani","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2217\/imt.14.86","article-title":"Current advances in T-cell-based cancer immunotherapy","volume":"6","author":"Wang","year":"2014","journal-title":"Immunotherapy"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2217\/imt.15.57","article-title":"Antibody-based immunotherapy of solid cancers: Progress and possibilities","volume":"7","author":"Nicodemus","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/1535370215584936","article-title":"From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy","volume":"240","author":"Firor","year":"2015","journal-title":"Exp. Biol. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.abb.2012.02.011","article-title":"Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays","volume":"526","author":"Golay","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/eji.201344179","article-title":"Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity","volume":"44","author":"Anikeeva","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.4049\/jimmunol.1301249","article-title":"Glycoengineering of therapeutic antibodies enhances monocyte\/macrophage-mediated phagocytosis and cytotoxicity","volume":"192","author":"Herter","year":"2014","journal-title":"J. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","article-title":"Macrophages are critical effectors of antibody therapies for cancer","volume":"7","author":"Weiskopf","year":"2015","journal-title":"mAbs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.exphem.2006.09.008","article-title":"Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils","volume":"35","author":"Krauth","year":"2007","journal-title":"Exp. Hematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.leu.2403350","article-title":"High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients","volume":"18","author":"Boeckx","year":"2004","journal-title":"Leukemia"},{"key":"ref_75","first-page":"118","article-title":"Effectiveness of Gemtuzumab Ozogamicin (Mylotarg) Treatment: Cellular and Systemic Determinants","volume":"12","author":"Velden","year":"2006","journal-title":"EJHP Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2007.05.011","article-title":"Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy","volume":"120","author":"Siebenhaar","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.anai.2013.08.014","article-title":"Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis","volume":"111","author":"Matito","year":"2013","journal-title":"Ann. Allergyasthma Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaip.2014.03.009","article-title":"Omalizumab as a desensitizing agent and treatment in mastocytosis: A review of the literature and case report","volume":"2","author":"Sokol","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2015-03-637728","article-title":"Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis","volume":"126","author":"Blatt","year":"2015","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/(SICI)1097-0320(19981015)34:5<223::AID-CYTO3>3.0.CO;2-B","article-title":"Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface","volume":"34","author":"Escribano","year":"1998","journal-title":"Cytometry"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1038\/nmeth.f.229","article-title":"Selecting reagents for multicolor flow cytometry with BD\u2122 LSR II and BD FACSCanto\u2122 systems","volume":"5","author":"Maecker","year":"2008","journal-title":"Nat. Methods"},{"key":"ref_82","first-page":"1.30.1","article-title":"A Quantitative Method for Comparing the Brightness of Antibody-dye Reagents and Estimating Antibodies Bound per Cell","volume":"77","author":"Kantor","year":"2016","journal-title":"Curr. Protoc. Cytom."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/3\/552\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:29:10Z","timestamp":1760185750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/3\/552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":82,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["ijms20030552"],"URL":"https:\/\/doi.org\/10.3390\/ijms20030552","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,28]]}}}